Hanmi announces start on Phase 3 clinical trials for ‘efpeglenatide’ in 2017
On the 28th, Hanmi Pharm(CEO Kwan-Soon Lee) announced it plans to start Phase 3 clinical trials of a new antidiabetic, whose license was agreed with Sanofi last year, ‘efpeglenatide,’ in 2017.
Hanmi Pharm and Sanofi was originally planning to have the Phase 3 clinical trials in the 4th quarter ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
